An Aging, Ailing World Sets the Stage For Very Healthy Profits

4 reasons to Own Our Favorite
Medical Devices ETF Now!

5 ETF Myth Busters It's just a short matter of time before gray-haired, retired folks in this world outnumber the toddler population. This historical shifting of demographics will no doubt lead to unprecedented demand for life-sustaining, state-of-the-art medical devices.

Imagine how the health care industry might be affected if one of every eight persons roaming the face of the earth were age 65 or older.

That may be reality come 2030 when it is projected that these 60-somethings will number 1 billion; and—like America's elderly today—the majority are likely to develop a chronic disease in their lifetime.

Common conditions like hypertension, arthritis, heart disease, cancer, diabetes and sinusitis will persist 20+ years from now—only more people will suffer from them.

Unless someone discovers a cure-all magic pill or the modern-day miracle Fountain of Youth, medical-device companies—and their shareholders—stand to make a heap of money from the development and manufacturing of equipment that can cure or manage these chronic conditions.

Still, it's a tricky sector to navigate. In an economy where health care stocks generally buck a recession-driven downtrend, many remain in the red.

About David Frazier

Hi, I am the editor of The ETF Strategist, published by Newsmax. I also contribute a weekly commentary in the Global Economic Briefing e-letter, which is read by more than 165,000 investors each week.
I have a diverse background in the financial services industry, having worked for such well-known firms as The Dun & Bradstreet Corporation, TD Ameritrade, and William O'Neil & Co. (the publisher of Investor's Business Daily).
While working as an equity analyst in 2003-2004, my stock recommendations generated an average annual return of 45.7%, compared to 19% for the S&P 500.
My Asset & Sector Allocation Model uses 97 financial and economic variables and 13 investor sentiment indicators to identify the current stage of the business cycle and determine which asset classes and economic sectors are likely to perform best in the next 3 to 6 months.
This model reveals whether or not to invest in ETFs comprised of stocks, bonds, commodities, precious metals, or real estate, as well as sectors such as basic materials, financial, or healthcare, or in foreign markets.
My Relative Performance Model ranks the price performance of the major economic sectors — 130 industries within those sectors — relative to the others over the most recent week, month and three-month timeframes.
This is a momentum model that identifies the sectors and industries that have recently been improving in performance, and are likely to continue to move up in rank as well as those that are falling back.
These two models reveal which sectors and industries show weakness and should be avoided.
After identifying which asset classes, economic sectors, and specific industries are most likely to be the top performers in the coming months, I use my ETF Comparison Model to analyze every ETF with significant holdings in our target market segments.
This model compares the historical performance records of ETFs during various market environments and helps determine which ones are the most likely to produce the best risk-adjusted results.
No other investment product captures the big financial moves as well as ETFs, but you need to know which ETFs are the best to buy!
That's where The ETF Strategist comes in.

The ETF Strategist knows the inroads to profitable health care investments—for today and tomorrow. In our next issue, you'll discover 4 reasons why you should own medical devices NOW!

Reason No. 1: Growing Sales and Earnings
Health care spending in the United States will more than double to $4.3 trillion by 2017, from $2.1 trillion in 2007, according to government estimates. That means spending in this arena will account for 20 percent of the nation's total output of goods and services, or $13,000 per person by 2017, as compared to $7,000 per person in 2007.

Reason No. 2: Bargain Prices
ETF Strategist research indicates that stocks of medical-device companies are currently priced relatively low, so now is a great buying opportunity.

Reason No. 3: Money Flowing into Medical Devices
Institutional money is beginning to pour into this industry, and individual investors should continue rotating a slice of their portfolios to defensive sectors.

Reason No. 4: Medicare Pays
Money usually isn't a factor. Medicare foots the bill when a person needs a life-saving medical device or one that retains a person's quality of life. Medicare covers 94 percent of Americans aged 65 and older, while 60 percent have some type of private health insurance.

Investors Beware

A word of warning, though: When it comes to choosing the right companies, it's easy to follow the masses and drift down a losing path. You can't just invest in a company because it makes headlines every day, manufactures your monthly prescription, or keeps your grandmother's heart beating. A single FDA denial, recall or missed launch could send any stock awry.

Plus, no sector is immune from the volatility enveloping the stock market these days. You can almost count on pullbacks at any time, taking down specific sectors or the broad market or both.

In the next issue of The ETF Strategist, we'll give you names those investments with the best potential for profiting in this sector. We'll also give you prudent advice on how much of your portfolio to allocate to medical devices, and set realistic sell prices that allow you to capture profits—and hang onto them.

To download the next issue and all of our current ETF recommendations, simply click here now.

What's Hot? Defibrillators, Pacemakers, Artificial Joints and Cancer Killers…To Name A Few

We're eying a conglomerate of companies that develop and manufacture all of the above and more, including:

A maker of devices that help the human heart to beat normally, such as defibrillators and pacemakers, heart valve replacement, and to alleviate malignant pain. This company recently received approval from the FDA for a stent system for use in the treatment of coronary artery disease, a condition affecting nearly 13 million people in the United States.
A designer of reconstructive implants used in knee-or hip-replacement surgery; shoulder implants that restore function in arthritic joints; spinal implants to fix aching or injured backs; and trauma products (such as plates, screws, and pins) that help broken bones to heal.
A manufacturer of artificial joints, spinal rods and screws, artificial vertebral · discs, bone cement, and other orthopedic implants and supplies. It has more than 480 clinics in 31 states throughout the United States.
A producer of non-invasive robotic radio surgery system that uses image-guidance technology and computer-controlled robotics to track, detect, and destroy cancer tumors anywhere in the body.
A provider of minimally invasive surgery systems that allow the surgeon to work through small incisions in a patient's body.

Sign up TODAY by clicking here.

The ETF Strategist: The Smart Road To Wealth

This, in a nutshell, is the beauty of The ETF Strategist. Our research and strategic models identify those sectors with strongest momentum and opportunities for profit. We make it sound easy, but it's not something you want to delve into on your own.

You've got to know which trends are legitimate; you need a gauge to tell you when to buy into a specific industry; what countries and companies are taking the lead, and just as importantly, you need to know how to identify when trends begin to peter out so you can pocket your profits instead of watching them evaporate.

Buying industry or country-specific stocks and holding onto them "forever," is a recipe for disaster. Like we said in our last issue of The ETF Strategist, a buy-and-hold strategy, highly touted by those brokers who always tell you to "buy, buy, buy," is one of the 5 Biggest Myths on Wall Street.

Sure, if you buy-and-hold during a roaring 10-year bull market, like many did from 1990-2000, you stand to profit handsomely. That false sense of security courtesy came to a screeching halt as trillions of dollars went up in smoke. Only smart money exited before the technology bubble burst. Today's version: Real estate and financials.

If you think—or would like to believe—that the latest round of up moves in the market is a sign of a bottom, you'd better brace yourself. Emotions and gut feelings have no place in this climate. Our technical indicators clearly show that major stock indices have failed to break through price-resistance points, with little impetus on the horizon to propel them further.

While many investors have struggled over the past year, The ETF Strategist has achieved market-beating returns for its followers.

Since its inception, our Aggressive Portfolio is up 21.8% are up, with two of our short positions holding onto 37.6% and 26.1% gains since 9/18/07. Meanwhile, the S&P 500's total return since then is -11.6%.

Even our Conservative Portfolio, designed for people wanting to preserve capital, is up 6.5% since 9/17/07, with a short S&P 500 ETF anchoring it with a 15.2% gain.

We firmly believe that The ETF Strategist has yet to reach its profit potential. Our goal each and every month is to show you how to hit the "sweet spot" of exceptional growth and make 25% to 50% profits over the next 3, 6 and 12 months.

With so many sectors beaten down, huge buying opportunities are just around the corner for those savvy investors able to identify the real deals.

In addition to our medical devices recommendations, in the next issue of The ETF Strategist, we give 3 Action Items you cannot afford to miss. These are must-do things to do NOW to prepare for whatever the market dishes out in the weeks to come.

Sign up for your risk-free subscription today.

60 Days Risk Free!

That's right, your ETF Strategist subscription is completely risk-free. If for any reason you don't like the service, just let us know within the first 60 days and you'll get a full refund — or anytime later for a refund on the remaining portion of your subscription. No questions asked.

You must be thrilled with the profits The ETF Strategist makes you or cancel anytime during the first 60 days for a 100% refund. Whatever you decide, you can keep everything you received.

That includes everything you need to know to begin profiting immediately from the tremendous opportunities ETFs offer — starting with how to make big profits in the coming year from the most explosive profit waves.

You'll get a monthly newsletter that highlights the asset classes, economic sectors, and industries that are poised to generate the biggest gains over the coming months, as well as Buy/Sell Alerts via email when opportunities to profit arise between issues.

Also in between monthly issues you'll stay up-to-date via our Weekly E-Mail Update. These are sent every Friday when the market is open to review the past weeks activities that may have affected our holdings. So we'll always be in touch with me.

In addition, you'll get the following 5 FREE special reports just for giving us a try:

cover Cash in on the Global Aging Profit Wave.
By 2015, people older than 65 are expected to outnumber children younger than 5 for the first time in history. By the year 2030, more than 1 billion people worldwide are projected to be older than 65..

cover Cash in on the New ETF Boom.
The Bible of ETF investing. Everything you need to start making big money with ETFs.

cover
If You Could Buy Just One ETF for the Next 12-Months.
If you are looking for just one investment for the coming year, go no further. This is it.

cover The ETF Lemon List: 99 ETFs You Must Avoid Now.
Don’t go near any of these dogs. Owning just one of these could torpedo your entire portfolio. If you own any of these, dump them now!

cover 10 Secrets Every ETF Investor Should Know
How to go quadruple long or short the market, how to create your own basket of stocks ETF, best way to trade currencies, collect big dividend checks and more!

Consider these reports a gift. It's our way of saying "thank you" for giving The ETF Strategist a try.

At just $249 a year, The ETF Strategist is a tremendous value. Just a single recommendation from one issue or any of these valuable special reports could easily earn you 100 times the cost of the subscription.

So what are you waiting for?